{"issuance_frequency":"","notes_translated":{"fr":"Le Relevé des maladies transmissibles au Canada est une publication bilingue et libre d'accès revue par un comité de lecture portant sur la prévention et le contrôle des maladies infectieuses nouvelles et tenaces.","en":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.\r\n"},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"P1M","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"edd826cd-b915-47f7-b8d8-add3c59c978f","metadata_created":"2021-06-21T18:21:08.761255","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-09-27T20:02:25.829418","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-21","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["vaccin","SRAS-CoV-2","acide","nucléique","coronavirus","SRAS‑CoV‑2","COVID‑19","épidémiologie","Canada","caractère","saisonnier","Surveillance","génomique","séquençage","génomique","COVID-19","variants préoccupants","santé publique","surveillance","distanciation","sociale","distanciation","physique","influenza","interventions","non pharmaceutiques","INP","rougeole","santé","des voyageurs","éradication","rougeole","vaccination","maladies","infectieuses","courtage","connaissances","acceptation","vaccins","hésitation","à la vaccination","interventions","évaluations","Programmes","vaccination","adaptés","programmes","TIP","RMTC"],"en":["vaccine","SARS-CoV-2","nucleic","acid","coronavirus","COVID-19","epidemiology","Canada","seasonality","Genomic surveillance","genomic","sequencing","variants","concern","public health","surveillance","social","distancing","physical distancing","influenza","nonpharmaceutical","interventions","NPI","measles","travel health","measles elimination","vaccination","infectious diseases","knowledge","brokering","vaccine","acceptance","vaccine hesitancy","interventions","evaluation","Tailoring","Immunization","Programmes","TIP","CCDR"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"RMTC : Volume 47-3, mars 2021 : L'influenza et les autres virus respiratoires","en":"CCDR: Volume 47-3, March 2021: Influenza and Other Respiratory Viruses"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"956dd43b-3a64-4de8-8414-e61f10efbab3","related_relationship":"","name_translated":{"fr":"RMTC : Volume 47-3, mars 2021 : L'influenza et les autres virus respiratoires","en":"CCDR: Volume 47-3, March 2021: Influenza and Other Respiratory Viruses"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 47-3, March 2021: Influenza and Other Respiratory Viruses","language":["en"],"created":"2021-06-21T18:21:08.868811","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr.html","last_modified":null,"position":0,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8f860f5c-3cab-4a9d-9017-221073274a19","related_relationship":"","name_translated":{"fr":"RMTC : Volume 47-3, mars 2021 : L'influenza et les autres virus respiratoires","en":"CCDR: Volume 47-3, March 2021: Influenza and Other Respiratory Viruses"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 47-3, March 2021: Influenza and Other Respiratory Viruses","language":["fr"],"created":"2021-06-21T18:21:08.868818","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc.html","last_modified":null,"position":1,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1fdfb8d5-e939-42c1-b219-2b4c115b6e8c","related_relationship":"","name_translated":{"fr":"Vaccin contre le SRAS-CoV-2 : défis et considérations","en":"Vaccine against SARS-CoV-2: Challenges and considerations"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Vaccine against SARS-CoV-2: Challenges and considerations","language":["en"],"created":"2021-06-21T18:21:08.868821","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/sars-cov-2-vaccine-challenges-considerations.html","last_modified":null,"position":2,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"178048f7-556c-42fe-8fa2-ce326c884694","related_relationship":"","name_translated":{"fr":"Vaccin contre le SRAS-CoV-2 : défis et considérations","en":"Vaccine against SARS-CoV-2: Challenges and considerations"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Vaccine against SARS-CoV-2: Challenges and considerations","language":["fr"],"created":"2021-06-21T18:21:08.868824","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/defis-considerations-vaccin-sras-cov-2.html","last_modified":null,"position":3,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1ea53906-14fa-4510-8c45-aeab73cc105f","related_relationship":"","name_translated":{"fr":"Le caractère saisonnier du coronavirus et d'autres virus au Canada : les conséquences de la COVID-19","en":"Seasonality of coronaviruses and other respiratory viruses in Canada: Implications for COVID-19"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Seasonality of coronaviruses and other respiratory viruses in Canada: Implications for COVID-19","language":["en"],"created":"2021-06-21T18:21:08.868827","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/seasonal-patterns-coronavirus-respiratory-viruses.html","last_modified":null,"position":4,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"98c7acf9-58ce-4cf0-bed2-d7ee0bfe6739","related_relationship":"","name_translated":{"fr":"Le caractère saisonnier du coronavirus et d'autres virus au Canada : les conséquences de la COVID-19","en":"Seasonality of coronaviruses and other respiratory viruses in Canada: Implications for COVID-19"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Seasonality of coronaviruses and other respiratory viruses in Canada: Implications for COVID-19","language":["fr"],"created":"2021-06-21T18:21:08.868829","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/modeles-saisonniers-coronavirus-virus-respiratoires.html","last_modified":null,"position":5,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f66fecce-4cb5-4d8c-8ac5-bf4c6f277fc9","related_relationship":"","name_translated":{"fr":"Priorités nationales canadiennes de surveillance génomique des variants préoccupants existants et émergents de la COVID-19","en":"Canadian national COVID-19 genomics surveillance priorities for existing and emerging variants of concern"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian national COVID-19 genomics surveillance priorities for existing and emerging variants of concern","language":["en"],"created":"2021-06-21T18:21:08.868832","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/sars-cov-2-variants.html","last_modified":null,"position":6,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"531b8b3d-b104-4b28-9428-2e106909a5c1","related_relationship":"","name_translated":{"fr":"Priorités nationales canadiennes de surveillance génomique des variants préoccupants existants et émergents de la COVID-19","en":"Canadian national COVID-19 genomics surveillance priorities for existing and emerging variants of concern"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian national COVID-19 genomics surveillance priorities for existing and emerging variants of concern","language":["fr"],"created":"2021-06-21T18:21:08.868835","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/variants-sras-cov-2.html","last_modified":null,"position":7,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"eb443269-bf72-413a-b6ab-43da2c99ef41","related_relationship":"","name_translated":{"fr":"Incidence des interventions non pharmaceutiques sur la détection de l'influenza A et B en laboratoire au Canada","en":"Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada","language":["en"],"created":"2021-06-21T18:21:08.868837","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/epidemiologic-seasonal-influenza-covid-19-shutdowns.html","last_modified":null,"position":8,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"a555e92e-b31b-4ed8-94a8-6276c02b2589","related_relationship":"","name_translated":{"fr":"Surveillance de la rougeole au Canada, 2019","en":"Measles surveillance in Canada, 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Measles surveillance in Canada, 2019","language":["en"],"created":"2021-06-21T18:21:08.868840","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/measles-annual-surveillance-report-2019.html","last_modified":null,"position":9,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","id":"9506f954-17af-4c6f-bb1a-4e5c23c16d4d","state":"active","name_translated":{"fr":"Incidence des interventions non pharmaceutiques sur la détection de l'influenza A et B en laboratoire au Canada","en":"Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada","language":["fr"],"created":"2021-06-21T18:21:08.868843","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/epidemiologiques-grippe-saisonniere-fermetures-covid-19.html","last_modified":null,"position":10,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","id":"3fb4e097-d9c4-47e7-9799-382c03941d6a","state":"active","name_translated":{"fr":"Surveillance de la rougeole au Canada, 2019","en":"Measles surveillance in Canada, 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Measles surveillance in Canada, 2019","language":["fr"],"created":"2021-06-21T18:21:08.868845","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/rapport-annuel-surveillance-rougeole-2019.html","last_modified":null,"position":11,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f81428fe-ea2d-45e4-ad96-0b552549e174","related_relationship":"","name_translated":{"fr":"Courtage de connaissances sur les maladies infectieuses pour la santé publique","en":"Knowledge brokering on infectious diseases for public health"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Knowledge brokering on infectious diseases for public health","language":["en"],"created":"2021-06-21T18:21:08.868848","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/public-health-knowledge-brokering.html","last_modified":null,"position":12,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5670924b-d43c-4256-8652-8a3094099712","related_relationship":"","name_translated":{"fr":"Courtage de connaissances sur les maladies infectieuses pour la santé publique","en":"Knowledge brokering on infectious diseases for public health"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Knowledge brokering on infectious diseases for public health","language":["fr"],"created":"2021-06-21T18:21:08.868850","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/sante-publique-courtage-connaissances.html","last_modified":null,"position":13,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"64f6fcc4-8b4e-48ad-bae9-f66c8097ff91","related_relationship":"","name_translated":{"fr":"Concevoir des interventions adaptées pour éliminer les obstacles à la vaccination","en":"Designing tailored interventions to address barriers to vaccination"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Designing tailored interventions to address barriers to vaccination","language":["en"],"created":"2021-06-21T18:21:08.868853","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/vaccine-hesitancy.html","last_modified":null,"position":14,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9920913f-949c-4717-8c04-30d4c333d0c9","related_relationship":"","name_translated":{"fr":"Concevoir des interventions adaptées pour éliminer les obstacles à la vaccination","en":"Designing tailored interventions to address barriers to vaccination"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Designing tailored interventions to address barriers to vaccination","language":["fr"],"created":"2021-06-21T18:21:08.868855","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/hesitation-vaccination.html","last_modified":null,"position":15,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"cd236cde-d966-4676-bc2b-9cc56f7016d7","related_relationship":"","name_translated":{"fr":"Comment l'innocuité et l'efficacité des vaccins contre COVID-19 seront réglementées","en":"How COVID-19 vaccines will be regulated for safety and effectiveness"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"How COVID-19 vaccines will be regulated for safety and effectiveness","language":["en"],"created":"2021-06-21T18:21:08.868858","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-3-march-2021/covid-19-vaccine-safety-effectiveness.html","last_modified":null,"position":16,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"edd826cd-b915-47f7-b8d8-add3c59c978f","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8663b3b5-9d64-4d6e-a51a-fc4e9d7a1208","related_relationship":"","name_translated":{"fr":"Comment l'innocuité et l'efficacité des vaccins contre COVID-19 seront réglementées","en":"How COVID-19 vaccines will be regulated for safety and effectiveness"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"How COVID-19 vaccines will be regulated for safety and effectiveness","language":["fr"],"created":"2021-06-21T18:21:08.868860","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2021-47/numero-3-mars-2021/vaccin-covid-19-innocuite-efficacite.html","last_modified":null,"position":17,"revision_id":"2039a0a8-0c6d-434c-b917-f129e47e884d","resource_type":"website"}],"place_of_publication":[],"num_resources":18,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2021-03-31 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"edd826cd-b915-47f7-b8d8-add3c59c978f","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.\r\n","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"CCDR: Volume 47-3, March 2021: Influenza and Other Respiratory Viruses","revision_id":"048bc3ab-a756-4072-b179-f4862e90bdbc"}